Athira Pharma is a biopharmaceutical company that focuses on developing small molecules to slow neurodegradation. Its lead product, ATH-1017, is in clinical trials for Alzheimer's and Parkinson's disease. The company also develops additional product candidates for peripheral nervous system indications and neuropsychiatric conditions.